跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
TEPMETKO - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
TEPMETKO
Authorized
STANDARD
TEPMETKO
emd serono, a division of emd inc., canada
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
dda6c4424968181a
Company
emd serono, a division of emd inc., canada
Type
Standard
Approval Details
Approval Id
dda6c4424968181a
Drug Approval Canada Name
TEPMETKO
Product Name
TEPMETKO
Status
Marketed
Status Date
2021-10-07
Original Market Date
2021-10-07
Din
02516322
Drug Class
Human
Dosage Form
Tablet
Route Of Administration
Oral
Schedule
Prescription
Ahfs
10:00.00
Atc Original
L01EX21 TEPOTINIB
Atc Name
l 01 ex 21
Aig Number
0162948001
Company Name
emd serono, a division of emd inc., canada
Company Address
2695 North Sheridan Way, Suite 200, Mississauga, Ontario, Canada, L5K 2N6
Active Ingredients
TEPOTINIB (TEPOTINIB HYDROCHLORIDE)
225 MG
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
dda6c4424968181a
Type
Standard
Back to Health Canada Approvals